Response assessment criteria for brain metastases: proposal from the RANO group


CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from most clinical trials, but their inclusion is now becoming more common. The medical literature is difficult to interpret because of substantial variation in the response and progression criteria used across clinical trials. The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases. Previous efforts have focused on aspects of trial design, such as patient population, variations in existing response and progression criteria, and challenges when incorporating neurological, neuro-cognitive, and quality-of-life endpoints into trials of patients with brain metastases. Here, we present our recommendations for standard response and progression criteria for the assessment of brain metastases in clinical trials. The proposed criteria will hopefully facilitate the development of novel approaches to this difficult problem by providing more uniformity in the assessment of CNS metastases across trials.

Introduction

Brain metastases are the most common cause of malignant brain tumours in adults. Of the nearly 1·5 million patients in the USA who received a primary diagnosis of cancer in 2007, about 70 000 of these primary diagnoses are estimated to eventually relapse in the brain.1,2 Despite the frequency of brain metastases, prospective trials in this patient population are limited, and the criteria used to assess response and progression in the CNS are heterogeneous.3 This heterogeneity largely stems from the recognition that existing criteria sets, such as RECIST,4,5 WHO,6 or Macdonald Criteria,7 are themselves distinct and have gaps and limitations in their ability to address issues specific to the assessment of patients with brain metastases (table 1).3 Key issues in the imaging of CNS metastases include the modality and frequency of assessment, the method of measurement (linear, bidimensional, volumetric), the magnitude of change that defines response or progression, differentiation between tumour-related and treatment-related changes, the inclusion (or exclusion) of corticosteroid use and clinical signs and symptoms with imaging definitions of progression and response, and the inclusion (or exclusion) of systemic disease status into the definition of CNS response and progression.

Scope and purpose of the proposed RANO-BM criteria

Prospective clinical trials to assess new treatments for patients with active brain metastases are becoming increasingly common. Additionally, we welcome the trend away from automatic exclusion of patients with brain metastases from clinical trials of novel therapies. The concurrent proliferation of response criteria for assessment of CNS metastases has made interpretation of trial results challenging. The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group first convened in 2011 to review the medical literature and propose new standard criteria for the radiological assessment of brain metastases in clinical trials. As reported in a previous review,8 the group acknowledges that objective response or progression-free survival, or both, might not always be the most relevant primary study endpoints, depending on the patient population, the treatment being assessed, and question being asked and that neuro-cognition and quality-of-life might be of greater importance in some settings. However, if an investigator chooses to include objective response or progression as key endpoints, we believe the trial community would be best served if the endpoints are assessed and defined more uniformly than they are at present. The criteria we propose are relevant for the assessment of parenchymal brain metastases only and do not cover leptomeningeal metastases, which are generally not radiographically measurable in a reliable and reproducible manner. Response criteria for leptomeningeal metastases will be assessed by a different RANO group. The proposed criteria for brain metastases also do not cover dural metastases or skull metastases invading the brain.

Process of RANO-BM criteria development

The RANO-BM is an international group of experts in medical oncology, neuro-oncology, radiation oncology, neurosurgery, neuroradiology, neuropsychology, biostatistics, and drug development who, in collaboration with government and industry partners, are working towards the development of more streamlined and broadly acceptable criteria for assessment of brain metastases. After completion of a literature review and critique, the group convened a series of meetings and regular teleconferences to formulate the following proposal for
## Table 1: Comparison of standard response criteria

<table>
<thead>
<tr>
<th>Imaging modality</th>
<th>Target lesion</th>
<th>Maximum number of CNS target lesions</th>
<th>Measurement technique</th>
<th>Shrinkage required for partial response</th>
<th>Confirmatory scans</th>
<th>Steroids</th>
<th>Neurological symptoms</th>
<th>Extracranial disease</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>RECIST 1.0</strong></td>
<td>CT or MRI</td>
<td>Longest diameter ≥10 mm</td>
<td>Unidimensional</td>
<td>≥30%</td>
<td>Required in non-randomised trials where response in the primary endpoint</td>
<td>Not included</td>
<td>Not included</td>
<td>Included</td>
</tr>
<tr>
<td><strong>RECIST 1.1</strong></td>
<td>CT or MRI</td>
<td>Longest diameter ≥10 mm</td>
<td>Unidimensional</td>
<td>≥20%</td>
<td>Required in non-randomised trials where response in the primary endpoint</td>
<td>Not included</td>
<td>Not included</td>
<td>Included</td>
</tr>
<tr>
<td>Macdonald7</td>
<td>CT or MRI</td>
<td>Minimum size not specified</td>
<td>Bidimensional</td>
<td>≥50%</td>
<td>Required at least 1 month apart</td>
<td>Stable or decreased</td>
<td>Stable to improved</td>
<td>Not applicable</td>
</tr>
<tr>
<td>WHO6</td>
<td>Not specified</td>
<td>Minimum size not specified</td>
<td>All lesions</td>
<td>Bidimensional</td>
<td>Required at least 4 weeks apart</td>
<td>Not included</td>
<td>Not included</td>
<td>Included</td>
</tr>
<tr>
<td>RANO (high-grade glioma)8</td>
<td>CT or MRI</td>
<td>Contrast-enhancing lesions with two perpendicular diameters ≥10 mm</td>
<td>At least two lesions, and up to five lesions in patients with multiple lesions*</td>
<td>Bidimensional</td>
<td>Required at least 4 weeks apart</td>
<td>Stable or decreased compared with time of baseline scan</td>
<td>Stable to improved clinically</td>
<td>Not applicable</td>
</tr>
</tbody>
</table>

*For patients with multiple lesions, of which only one or two are increasing in size, the enlarging lesions should be considered the target lesions and other lesions will be considered non-target lesions.

**Definitions**

Measurable disease is defined as a contrast-enhancing lesion that can be accurately measured in at least one dimension, with a minimum size of 10 mm, and is visible on two or more axial slices that are preferably 5 mm or less apart with 0 mm skip (and ideally ≤1.5 mm apart with 0 mm skip). Additionally, although the longest diameter in the plane of measurement is to be recorded, the diameter perpendicular to the longest diameter in the plane of measurement should be at least 5 mm for the lesion to be considered measurable. If the MRI is performed with thicker slices, the size of the measurable lesion at baseline should be at least double the slice thickness. Interslice gaps, if present, should also be considered in the determination of the minimum size of measurable lesions at baseline. Measurement of a tumour around a cyst or surgical cavity is a particularly difficult challenge. Generally, such lesions should be considered non-measurable unless there is a nodular component that measures 10 mm or more in longest diameter and 5 mm or more in the perpendicular plane. The cystic or surgical cavity should not be measured for the determination of a response (figure 1).

Non-measurable disease includes all other lesions, including lesions with longest dimension less than 10 mm, lesions with borders that cannot be reproducibly measured, dural metastases, bony skull metastases, cystic-only lesions, and leptomeningeal disease.

We recognise that many patients with brain metastases present with small sub-centimetre lesions and that some centres routinely perform MRI imaging with 3 mm slice thickness or less. We have discussed whether the lower size limit of a measurable lesion could be reduced to 5 mm or even less. However, in view of concerns about reproducibility and interpretation of changes in small lesions, the overall consensus was to maintain consistency with RECIST 1.1. Patients with non-measurable disease can still be included in trials where response is not the primary endpoint (eg, in trials with progression-free survival, overall survival, or other primary endpoints). For studies in which CNS objective response is the primary endpoint, we generally recommend a cutoff of 10 mm to limit the study to measurable disease.

For investigators who choose to lower the minimum size limit of measurable disease to 5 mm, we strongly recommend MRI imaging with 1-5 mm slice thickness or less. Complete response and unequivocal progressive disease can probably be interpreted even with lesions as small as 5 mm. However, measurement of small changes, such as the minimum 20% increase in longest diameter to determine progressive disease or the minimum 30% decrease in longest diameter to determine partial response, might not be robust or reproducible. With the intrinsic uncertainty of measurements of small lesions, any lesion less than 10 mm in longest diameter should be
regarded as unchanged from baseline unless there is a minimum 3 mm change in the measured longest diameter.

The decision to include patients with multiple lesions with a sum diameter of 10 mm or more but of which the largest lesion measures less than 10 mm should be taken with caution if objective response is the primary endpoint. If such patients are included, response should be assessed using the sum of the longest diameters of the lesions, and the response criteria should be clearly delineated in the protocol. Thin-section MRI imaging with 1·5 mm or thinner slice thickness would be necessary in this setting (appendix).

Methods of measurement
The same method of assessment and the same technique should be used to characterise each identified and reported lesion at baseline and during follow-up. Consistent use of imaging techniques across all imaging timepoints is important to ensure that the assessment of interval appearance, disappearance of lesions, or change in size is not affected by scan parameters such as slice thickness. Use of thin section imaging (appendix) is particularly important for the assessment of lesions less than 10 mm in longest diameter or small changes in lesion size, or both.

Gadolinium-enhanced MRI is the most sensitive and reproducible method available to measure CNS lesions selected for response assessment. Suggested brain MRI specifications are detailed in the appendix. MRI is strongly encouraged as the default standard imaging technique, although CT with and without contrast could be encouraged as the default standard imaging technique, although CT with and without contrast could be considered in specific circumstances (eg, countries with limited medical resources or contraindication for MRI).

Tumour-response assessment
Only patients with measurable CNS disease at baseline should be included in protocols where objective CNS tumour response is the primary endpoint. For studies in which objective response is not the primary endpoint, the protocol must specify prospectively whether entry is restricted to those with measurable disease or if patients with non-measurable disease are also eligible. Assignment of CNS response is independent of systemic disease response. CNS lesions are to be assessed according to RANO-BM criteria, whereas non-CNS lesions would most typically be assessed according to RECIST 1·1 criteria. Generally, CNS lesions should initially be re-assessed by MRI at protocol-specified intervals 6–12 weeks apart, although there might be specific circumstances in which longer (or shorter) intervals are desirable. For patients who remain stable for extended periods of time, a longer interval between scans might be appropriate.

All baseline assessments should be done as close as possible to the treatment start and no more than 4 weeks before the beginning of treatment. For previously treated lesions, we recommend documentation of how each lesion was previously treated (eg, stereotactic radiosurgery, whole brain radiotherapy, surgical resection). When more than one measurable lesion in the CNS is present at baseline, all lesions up to a maximum of five CNS lesions should be identified as target lesions and will be recorded and measured at baseline. All measurements should be recorded in metric notation. Target lesions should be selected on the basis of their size (longest diameter) and as those that can be measured reproducibly. For patients with recurrent disease who have multiple lesions, of which only one or two are increasing in size, the enlarging lesions should be prioritised as target lesions for the response assessment. Lesions with prior local treatment (ie, stereotactic radiosurgery or surgical resection) can be considered measurable if progression has occurred since the time of local treatment. However, careful consideration should be given to lesions previously treated with stereotactic radiosurgery, in view of the possibility of treatment effect, which we discuss below. Whether such lesions can be considered measurable should be specified prospectively in the clinical protocol. If lesions not previously treated with local therapies are present, these are preferred for selection as target lesions. A sum of the diameters for all target lesions will be calculated and reported as the baseline sum of longest diameters. All other CNS lesions should be identified as non-target lesions and should also be recorded at baseline. Measurements are not required and these lesions should be classified as present, absent, or unequivocal progression, and followed up.
Panel 1: Response assessment of target and non-target lesions

**Target lesions**
- **Complete response**: Disappearance of all CNS target lesions sustained for at least 4 weeks; with no new lesions, no use of corticosteroids, and patient is stable or improved clinically.
- **Partial response**: At least a 30% decrease in the sum longest diameter of CNS target lesions, taking as reference the baseline sum longest diameter sustained for at least 4 weeks; no new lesions; stable to decreased corticosteroid dose; stable or improved clinically.
- **Progressive disease**: At least a 20% increase in the sum longest diameter of CNS target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, at least one lesion must increase by an absolute value of 5 mm or more to be considered progression.
- **Stable disease**: Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease, taking as reference the smallest sum longest diameter while on study.

**Non-target lesions**
- **Non-target lesions should be assessed qualitatively at each of the timepoints specified in the protocol.**
- **Complete response**: Requires all of the following: disappearance of all enhancing CNS non-target lesions, no new CNS lesions.
- **Non-complete response or non-progressive disease**: Persistence of one or more non-target CNS lesion or lesions.
- **Progressive disease**: Any of the following: unequivocal progression of existing enhancing non-target CNS lesions, new lesion(s) (except while on immunotherapy-based treatment), or unequivocal progression of existing tumour-related non-enhancing (T2/FLAIR) CNS lesions. In the case of immunotherapy-based treatment, new lesions alone may not constitute progressive disease.

**Definition of best overall CNS response**
Best overall CNS response is a composite of radiographical CNS target and non-target lesion responses (panel 1), corticosteroid use, and clinical status. For non-randomised trials in which CNS response is the primary endpoint, confirmation of partial response or complete response at least 4 weeks later is necessary to deem either one the best overall response.

At each protocol-specified timepoint, a response assessment should occur and CNS assessments should be coincident with extra-CNS assessment. Table 2 shows the additional corticosteroid and clinical status requirements to deem a partial response or complete response.

**Assessment of target and non-target CNS lesions**
While on study, all CNS target lesions should have their actual measurement recorded, even if very small (eg, 2 mm). If the lesion disappears, the value should be recorded as 0 mm. However, if the lesion is sufficiently small (but still present) to be assigned an exact measure, a default value of 5 mm should be recorded on the case report form.

Lesions might coalesce during treatment. As lesions coalesce, a plane between them may be maintained that would aid in obtaining maximum longest diameter of each individual lesion. If the lesions have truly coalesced such that they are no longer separable, the vector of the longest diameter in this instance should be the maximum longest diameter for the coalesced lesion.

New lesions can appear during treatment. The finding of a new CNS lesion should be unequivocal and not due to technical or slice variation. A new lesion is one that was not present on prior scans. If the MRI is obtained with slice thickness of 1·5 mm or less, the new lesion should also be visible in axial, coronal, and sagittal reconstructions of 1·5 mm or thinner projections. If a new lesion is equivocal, for example because of its small size (ie, ≤5 mm), continued therapy can be considered, and a follow-up assessment will clarify if it really is new disease. If repeated scans confirm a new lesion, progression should be declared using the date of the initial scan showing the new lesion. In the case of immunotherapy, however, new lesions alone cannot constitute progressive disease.

Unequivocal progression of non-target lesions can merit discontinuation of therapy. When a patient also has measurable disease, to be deemed as having unequivocal progression on the basis of non-target disease alone there must also be an overall substantial worsening in non-target disease such that, even in the presence of stable disease or partial response in target disease, the overall tumour burden has increased sufficiently to merit discontinuation of therapy. When the patient has only non-measurable disease, there must be an overall level of substantial worsening to merit discontinuation of therapy.

The RANO-BM group acknowledges the case of patients who have been treated with stereotactic radiosurgery or immunotherapy-based approaches, for whom there has been radiographical evidence of enlargement of target and non-target lesions, which do not necessarily represent tumour progression. If radiographical evidence of progression exists, but clinical evidence indicates that the radiological changes are due to treatment effect (and not to progression of cancer), additional evidence is needed to distinguish between true progression and treatment effect, in which case standard MRI alone is insufficient. The methods used to distinguish between true progression and treatment effect should be specified prospectively in the clinical protocol. Patients can be continued on protocol therapy pending further investigation with one or more of the following options.

The scan can be repeated at the next protocol-scheduled assessment or sooner, and generally within about 6 weeks. An investigator can choose a shorter time interval if progressive symptoms or other clinical concerns arise. Continued tumour growth might be consistent with
radiographical progression, in which case the patient should leave the study (figure 2). Stabilisation and shrinkage of a lesion can be consistent with treatment effect, in which case the patient can stay in the study (figure 3). For patients with equivocal results even on the next restaging scan, the scan can be repeated again at a subsequent protocol-scheduled assessment or sooner, although surgery or use of an advanced imaging modality (in the case of stereotactic radiosurgery), or both, are strongly encouraged. Surgical pathology can be obtained via biopsy or resection.

For lesions treated by stereotactic radiosurgery, additional evidence of tumour progression or treatment effect (radionecrosis) can be acquired with an advanced imaging modality, such as perfusion MRI, magnetic resonance spectroscopy, or $^{18}$FLT or $^{18}$FDG PET. On the basis of a literature review and extensive discussions, we found the literature insufficiently robust to conclude

<table>
<thead>
<tr>
<th>Target lesions</th>
<th>Complete response</th>
<th>Partial response</th>
<th>Stable disease</th>
<th>Progressive disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Non-target lesions</td>
<td>None</td>
<td>&gt;30% decrease in sum longest distance relative to baseline</td>
<td>&gt;30% decrease relative to baseline but &lt;20% increase in sum longest distance relative to nadir</td>
<td>&gt;20% increase in sum longest distance relative to nadir*</td>
</tr>
<tr>
<td>Corticosteroids</td>
<td>None</td>
<td>Stable or improved</td>
<td>Stable or improved</td>
<td>Unequivocal progressive disease*</td>
</tr>
<tr>
<td>Clinical status</td>
<td>Stable or improved</td>
<td>Stable or improved</td>
<td>Stable or improved</td>
<td>Better*</td>
</tr>
<tr>
<td>Requirement for response</td>
<td>All</td>
<td>All</td>
<td>All</td>
<td>Any‡</td>
</tr>
</tbody>
</table>

*Progression occurs when this criterion is met. †A new lesion is one that not present on prior scans and is visible in minimum two projections. If a new lesion is equivocal, for example because of its small size, continued therapy can be considered, and follow-up assessment will clarify if the new lesion is new disease. If repeat scans confirm there is definitely a new lesion, progression should be declared using the date of the initial scan showing the new lesion. For immunotherapy-based approaches, new lesions alone to do not define progression. Increase in corticosteroids alone will not be taken into account in determining progression in the absence of persistent clinical deterioration.

Table 2: Summary of the response criteria for CNS metastases proposed by RANO-BM
Review

that any one modality or approach can be recommended across all patients to distinguish between radiation necrosis and true progression. Instead, we recommend clinical judgment and involvement of a multidisciplinary team. We recognise this recommendation is less than satisfactory and agree that more sensitive and specific methods to distinguish between treatment effect and tumour progression are needed. Note that these advanced imaging modalities have not been extensively studied with regards to immunotherapy-based approaches and therefore cannot be recommended to distinguish between tumour progression and immune-related changes at present. Irrespective of the additional testing obtained, if subsequent testing shows that progression has occurred, the date of progression should be recorded as the date of the scan this issue was first raised. Patients can also have an equivocal finding on a scan (eg, a small lesion that is not clearly new). Continued treatment is permissible until the next protocol-scheduled assessment. If the subsequent assessment shows that progression has indeed occurred, the date of progression should be recorded as the date of the initial scan where progression was suspected.

In patients receiving immunotherapy-based treatment, an initial increase in the number and size of metastases can be followed by radiographical stabilisation or regression.13 This pattern might be related to the mechanism of action of immunotherapy, including immune infiltrates, and the time to mount an effective immune response. Thus, progressive disease should not be solely defined by the appearance of new lesions but rather as a minimum 20% increase in the sum longest diameter of CNS target and new lesions, as unequivocal progression of existing enhancing non-target CNS lesions, as unequivocal progression of existing non-enhancing (T2/FLAIR) CNS lesions, or as clinical decline related to the tumour. If immune response-related radiographical changes are suspected, we advise to not change treatment until a short interval scan is obtained. If the subsequent assessment confirms that progression has indeed

Figure 3: Pseudoprogression of brain metastasis
Axial contrast-enhanced T1-w (A–C) and FLAIR images (D–F) of melanoma metastases before (A, D), on ipilimumab (B, E), and 6 weeks after end of immunotherapy (C, F). Note the right frontal metastases with contrast enhancement and perifocal oedema (A, C), which increase under therapy (B, E) and resolve without change of therapy (C, F).
adds cost and complexity and is not available at all centres.

volumetric analyses in real-time volumetric response criteria in clinical trials of patients yet strong enough to justify the universal requirement of The RANO-BM group judges that the existing data are not much discussion and debate within the RANO-BM group.

www.thelancet.com/oncology

related toxicity, or changes in corticosteroid dose. impairment is attributable to comorbid events, treatment-related neurological deterioration, unless this functional deterioration related to the tumour becomes apparent, they will be considered as having progressing.

The definition of clinical deterioration is left to the discretion of the treating physician, but it is recommended that patients who have a decrease in score on the Karnofsky performances scale from 100 or 90 to 70 points or less, a decrease of minimum 20 points from 80 or less, or a decrease from any baseline to 50 points or less, for at least 7 days, be considered as having neurological deterioration, unless this functional impairment is attributable to comorbid events, treatment-related toxicity, or changes in corticosteroid dose.

Volumetric criteria

Research of the value of volumetric versus unidimensional measurements for the assessment of CNS lesion response is ongoing. Volumetric measurement was the topic of much discussion and debate within the RANO-BM group. The RANO-BM group judges that the existing data are not yet strong enough to justify the universal requirement of volumetric response criteria in clinical trials of patients with brain metastases. Volumetric analyses in real-time adds cost and complexity and is not available at all centres. Yet, RANO-BM also believes that the assessment and reporting of volumetric response in clinical trials (in addition to the unidimensional RANO-BM criteria) will add to the knowledge base, either justify or negate the need for volumetric measurements in future trials, and encourage its inclusion as a secondary endpoint when feasible.

The appropriate cutoff to define a partial response on the basis of volumetric measurements was another topic of debate. If a tumour forms a perfect sphere, a 30% unidimensional reduction corresponds to about a 65% volumetric reduction, and there are data showing concordance of response assessments with these cut-offs in patients with brain metastasis. Also, volumetric changes of minimum 20% appear to be reproducible between readers, and results of one study showed that 20% or greater volumetric reduction was associated with improvements in neurological signs and symptoms.

The RANO-BM group believes that use of the same criteria and cutoffs across trials will allow trial results to be interpreted in their proper context. Thus, for investigators who choose to report volumetric response data, we propose the following. First, partial volumetric response should be defined as a 65% or greater decrease in the sum volume of CNS target lesions, in addition to the corticosteroid and clinical status criteria as outlined previously. Second, volumetric response should be reported as a waterfall plot to provide a global sense of potential efficacy. Third, in the absence of high quality data across multiple studies to show a clear correlation between lower volumetric thresholds and some measure of patient benefit, such as quality of life, neuro-cognitive function, or overall survival, it is premature to formally define a category of minor response or to lower the threshold at which to consider a volumetric response. However, we encourage digital archiving of trial images and accompanying linked clinical outcome data to allow

<table>
<thead>
<tr>
<th>CNS (RANO-BM)</th>
<th>Non-CNS (RECIST 1.1)</th>
<th>Bi-compartmental PFS</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response, partial response, or stable disease</td>
<td>Complete response, partial response, or stable disease</td>
<td>Log as CNS and non-CNS complete response, partial response, or stable diseases</td>
<td></td>
</tr>
<tr>
<td>Complete response, partial response, or stable disease</td>
<td>Progressive disease</td>
<td>Log as CNS complete response, partial response, or stable disease; log as non-CNS progressive disease</td>
<td></td>
</tr>
<tr>
<td>Progressive disease</td>
<td>Complete response, partial response, or stable disease</td>
<td>Log as CNS progressive disease; log as non-CNS complete response, partial response, or stable disease</td>
<td></td>
</tr>
<tr>
<td>Progressive disease</td>
<td>Progressive disease</td>
<td>Log as both CNS and non-CNS progressive disease</td>
<td></td>
</tr>
</tbody>
</table>

Table 3: CNS and non-CNS response assessment

<table>
<thead>
<tr>
<th>CNS (RANO-BM)</th>
<th>Non-CNS (RECIST 1.1)</th>
<th>Bi-compartmental PFS</th>
<th>Note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete response, partial response, or stable disease</td>
<td>Progressive disease</td>
<td>Log as a progression-free survival event</td>
<td>Log as non-CNS progressive disease</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>Complete response, partial response, or stable disease</td>
<td>Log as a progression-free survival event</td>
<td>Log as CNS progressive disease</td>
</tr>
<tr>
<td>Progressive disease</td>
<td>Progressive disease</td>
<td>Log as a progression-free survival event</td>
<td>Log as both CNS and non-CNS progressive disease</td>
</tr>
</tbody>
</table>

Table 4: Bi-compartmental progression-free survival

occurred, the date of progression should be recorded as the date of the initial scan where progression was suspected.

Corticosteroid use and clinical deterioration

In the absence of clinical deterioration related to the tumour, an increase in corticosteroid dose alone should not be used as a sole determinant of progression. Patients with stable imaging results and whose corticosteroid dose has increased for reasons other than clinical deterioration related to the tumour do not qualify as having stable disease or progression. These patients should be observed closely, and if their corticosteroid dose can be reduced back to baseline, they will be considered as having stable disease, but if further clinical deterioration related to the tumour becomes apparent, they will be considered as having progressing.

The definition of clinical deterioration is left to the discretion of the treating physician, but it is recommended that patients who have a decrease in score on the Karnofsky performances scale from 100 or 90 to 70 points or less, a decrease of minimum 20 points from 80 or less, or a decrease from any baseline to 50 points or less, for at least 7 days, be considered as having neurological deterioration, unless this functional impairment is attributable to comorbid events, treatment-related toxicity, or changes in corticosteroid dose.
for studies to be pooled to determine whether different cutpoints could be justified in the future.

**Treatment of non-CNS (extracranial) disease**

Preclinical and clinical data sometimes show a differential response in intracranial versus extracranial locations, which could be related to inadequate drug penetration, differences in tumour microenvironment, or tumour heterogeneity between organ sites, among other possibilities. Many systemic agents are not expected to have CNS activity, primarily because of poor drug penetration. Local CNS therapies, such as whole-brain radiotherapy, stereotactic radiosurgery, or surgery, are not expected to affect extracranial sites at all.

Traditionally, RECIST has used a summation of representative target lesions across all organ sites. Historically, patients with brain metastases have been excluded from systemic therapy trials. Even when included, patients with brain metastases often had to have stable, treated CNS lesions on study entry, and CNS lesions were rarely chosen as target lesions. The Macdonald and RANO-HGG criteria do not provide guidance about the treatment of extracranial disease, since extracranial disease is not relevant in most patients with primary brain tumours. The consequences have been an absence of flexibility to continue protocol therapy in the setting of discordant CNS versus non-CNS response or progression, a disincentive to image the brain as part of clinical trials, and the use of different definitions of response and progression endpoints in local therapy trials and systemic therapy trials.

We propose that CNS and non-CNS should be assessed as separate compartments (table 3). As such, CNS response will be scored irrespectively of extracranial response and vice versa. For progression, CNS and non-CNS will be scored according to RANO-BM and RECIST 1.1 criteria, respectively (table 4). If progression occurs in either or both compartments, the criteria for bi-compartmental progression-free survival will have been met. Protocols can also prospectively specify CNS progression-free survival and non-CNS progression-free survival as endpoints. Protocols should specify the plan for patients who progress in one compartment only. For example, a patient who develops isolated CNS progression in a systemic therapy trial can be given the option to have their CNS disease treated with whole-brain radiotherapy, stereotactic radiosurgery, or surgery and remain on protocol therapy until the time of non-CNS disease progression, unacceptable toxicity, or death. The date of non-CNS progressive disease should be recorded when it occurs.

**Additional endpoints for localised therapy trials**

Patients with brain metastases frequently undergo focal treatments such as surgical resection and stereotactic radiosurgery. With these modalities, the technical success of the treatment is appropriately measured by assessment of the site of localised therapy and not distant sites. For example, outcomes after stereotactic radiosurgery are commonly reported as local control (ie, control of the treated lesion) and distant brain failure (ie, the appearance of new or progressive lesions outside the treated field). This situation is analogous to breast cancer, in which trials of locoregional therapy will commonly report endpoints such as ipsilateral invasive breast cancer recurrence or regional invasive breast cancer recurrence.23 Panel 2 outlines the RANO-BM-proposed definitions of bicompartamental progression-free survival, CNS progression-free survival, non-CNS progression-free survival, and local CNS progression-free survival, which account for the variety of trial endpoints that might be chosen depending on the clinical situation, treatment modality, and overall study goal.

**Conclusion**

We recognise that our proposal adds complexity to the assessment of patients with brain metastases enrolled in clinical trials. However, limitations of the existing response criteria have led to frequent, but inconsistent, modifications by investigators. Additionally, because brain metastases can be treated using multiple modalities, which might or might not have effects outside of the treated field or outside the brain, endpoints in trials have also been defined differently according to the modality. Whereas the choice of primary and secondary endpoints will naturally vary according to the treatment modality, overall study goal, and study type (eg, proof of concept, technical validation, phase 3 registration study), we believe the definition of the endpoints should ideally remain constant. Frequently asked questions are listed and answered in the appendix.
Future plans include collaborations with RECIST investigators to analyse historical datasets and to solicit feedback from other investigators to refine the proposed criteria in future iterations. However, we should note that any retrospective analysis of historical datasets will be limited by the quality and nature of the recorded data. For example, because very few studies simultaneously collect unidimensional, bidimensional, and volumetric measurements, retrospective studies of large datasets are unlikely to provide answers to all of the questions raised above unless there is a large-scale effort to collect archival images and conduct central radiology review. In addition, because information for corticosteroid use, functional status, neurological symptoms, neuro-cognitive functioning, and quality of life were also variably collected and assessed, associations between response and functional outcomes will be challenging to validate. We would encourage investigators interested in the specialty of brain metastasis to strategise together on how best to gather the necessary common data elements across trials to allow such analyses in the future.

Contributors
All authors contributed to the literature search and writing of the report. MB prepared the figures.

Declaration of interests
DPB has a leadership position in ECOG-ACRIN and declares non-financial support from GE Medical Systems, outside the submitted work. BGB declares personal fees and non-financial support from Roche Pharma AG, academic institutions, and Bayer Pharma AG, outside the submitted work. MB declares grants and personal fees from Guerbet, Codman, Bayer, personal fees from Novartis and Vascular Dynamics, grants from Siemens, personal fees from Roche, outside the submitted work. FSH declares grants and non-financial support from Bristol-Myers Squibb, personal fees from Merck, non-financial support from Genentech, personal fees and non-financial support from Novartis, outside the submitted work; in addition, FSH has a patent immune therapy target pending. NUL declares grants from Breast Cancer Research Foundation, during the conduct of the study, grants to support clinical therapy target pending. NUL declares grants from Breast Cancer Research Foundation, but this support did not directly influence the writing of this manuscript or the decision to submit it for publication.

References